Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.

ABSTRACT:

Objective

To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.

Design

Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.

Setting

We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy.

Main outcomes and measures

Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official a

SUBMITTER: Trotta F 

PROVIDER: S-EPMC6924817 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature